X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (93) 93
humans (85) 85
oncology (72) 72
female (42) 42
colorectal neoplasms - drug therapy (37) 37
colorectal cancer (34) 34
colorectal neoplasms - genetics (34) 34
mutation (34) 34
animals (32) 32
cancer (32) 32
cell line, tumor (32) 32
male (28) 28
mice (26) 26
middle aged (26) 26
aged (25) 25
cetuximab (23) 23
antineoplastic agents - pharmacology (21) 21
colorectal neoplasms - pathology (21) 21
drug resistance, neoplasm (21) 21
adult (19) 19
aged, 80 and over (19) 19
receptor, epidermal growth factor - antagonists & inhibitors (19) 19
antineoplastic agents - therapeutic use (18) 18
chemotherapy (18) 18
genetic aspects (18) 18
ras proteins - genetics (18) 18
tumors (18) 18
proto-oncogene proteins b-raf - genetics (17) 17
therapy (17) 17
drug resistance, neoplasm - genetics (16) 16
resistance (16) 16
acquired-resistance (15) 15
kras (15) 15
proto-oncogene proteins p21 (15) 15
antibodies, monoclonal - therapeutic use (14) 14
beer (14) 14
biochemistry (14) 14
cell biology (14) 14
chemistry (14) 14
enzymology (14) 14
lung-cancer (14) 14
metallurgy (14) 14
metastasis (14) 14
microbiology (14) 14
mutation or genetic engineering (14) 14
mutations (14) 14
proto-oncogene proteins - genetics (14) 14
research (14) 14
spirits (14) 14
vinegar (14) 14
wine (14) 14
breast-cancer (13) 13
receptor, epidermal growth factor - metabolism (13) 13
analysis (12) 12
compositions or test papers therefor (12) 12
condition-responsive control in microbiological orenzymological processes (12) 12
health aspects (12) 12
human necessities (12) 12
hygiene (12) 12
measuring or testing processes involving enzymes, nucleicacids or microorganisms (12) 12
medical or veterinary science (12) 12
multidisciplinary sciences (12) 12
preparations for medical, dental, or toilet purposes (12) 12
processes of preparing such compositions (12) 12
amplification (11) 11
antibodies, monoclonal, humanized (11) 11
cells (11) 11
colon-cancer (11) 11
colorectal neoplasms - metabolism (11) 11
digestive system diseases (11) 11
egfr (11) 11
expression (11) 11
growth-factor receptor (11) 11
neoplasm metastasis (11) 11
organic chemistry (11) 11
panitumumab (11) 11
peptides (11) 11
article (10) 10
care and treatment (10) 10
cell lung-cancer (10) 10
neoplasms (10) 10
prognosis (10) 10
ras proteins - metabolism (10) 10
receptor, epidermal growth factor - genetics (10) 10
biomarkers (9) 9
carcinoma (9) 9
chemosensitivity (9) 9
colorectal carcinoma (9) 9
drug resistance, neoplasm - drug effects (9) 9
gene expression regulation, neoplastic (9) 9
genes, ras (9) 9
heterogeneity (9) 9
inhibition (9) 9
metastases (9) 9
neoplasms - drug therapy (9) 9
neoplasms - genetics (9) 9
protein kinase inhibitors - pharmacology (9) 9
proto-oncogene proteins b-raf - antagonists & inhibitors (9) 9
signal transduction - drug effects (9) 9
xenograft model antitumor assays (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2013, Volume 10, Issue 7, pp. 372 - 374
Tivantinib is being tested in a variety of phase II and phase III clinical trials as a highly selective, non ATP-competitive MET tyrosine kinase inhibitor. Its... 
ARQ 197 | PLACEBO | ONCOLOGY | INIPARIB | KINASE | Proto-Oncogene Proteins c-met - metabolism | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Tubulin Modulators - pharmacology | Humans | Pyrrolidinones - pharmacology | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Quinolines - pharmacology | Index Medicus
Journal Article
Molecular Oncology, ISSN 1574-7891, 09/2014, Volume 8, Issue 6, pp. 1084 - 1094
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer... 
Acquired resistance | RAS | Panitumumab | Colorectal cancer | Cetuximab | Anti-EGFR therapy | MET
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 1015 - 1015
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 3394 - 3394
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 02/2017, Volume 9, Issue 2, pp. 219 - 237
The development of resistance remains a major obstacle to long‐term disease control in cancer patients treated with targeted therapies. In BRAF ‐mutant mouse... 
vascular normalization | drug resistance | myeloid infiltration | angiogenesis | extracellular matrix | Vascular Biology & Angiogenesis | Skin | Cancer
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. LB-213 - LB-213
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 916 - 916
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
European Journal of Oncology, ISSN 1128-6598, 2015, Volume 20, Issue 1, pp. 5 - 6
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 35, pp. 5705 - 5712
Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately... 
GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | PROGNOSTIC-FACTOR | MUTATION STATUS | THERAPY | ONCOLOGY | MISMATCH-REPAIR | OPEN-LABEL | KRAS | GENE COPY NUMBER | CHEMOTHERAPY | Niacinamide - analogs & derivatives | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Phenylurea Compounds | Patient Selection | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Benzenesulfonates - pharmacology | Neoplasm Metastasis | Time Factors | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Cell Survival - drug effects | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Treatment Outcome | Switzerland | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Italy | Aged | Biomarkers, Tumor - genetics | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Mutation | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 10/2010, Volume 304, Issue 16, pp. 1812 - 1820
Journal Article
Human Mutation, ISSN 1059-7794, 02/2014, Volume 35, Issue 2, pp. 208 - 214
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 8 Supplement, pp. 4130 - 4130
Journal Article
Nature, ISSN 0028-0836, 06/2012, Volume 486, Issue 7404, pp. 532 - 536
Journal Article
Nature, ISSN 0028-0836, 2017, Volume 552, Issue 7683, pp. 1 - 5
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2013, Volume 10, Issue 7, pp. 372 - 374
Tivantinib is being tested in a variety of phase II and phase III clinical trials as a highly selective, non ATP-competitive MET tyrosine kinase inhibitor. Its... 
Usage | Control | Cancer cells | Monoclonal antibodies | Clinical trials | Research | Management | Health aspects
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 508, Issue 1, pp. 118 - 122
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably(1,2).... 
GROWTH-FACTOR RECEPTOR | BRAF INHIBITOR | RAF INHIBITION | CELLS | MULTIDISCIPLINARY SCIENCES | IMPROVED SURVIVAL | DIFFERENTIATION | C-JUN | CANCER | EXPRESSION | EGFR | Receptor, Epidermal Growth Factor - genetics | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Gene Library | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | Patients | Tumors | Index Medicus
Journal Article